Ofuxal (Alfuzosin Hydrochloride)

Alfuzosin hydrochloride, the active ingredient in Ofuxal, is an alpha‑1 adrenergic antagonist presented as a tablet for oral use. It is indicated for the treatment of lower urinary tract symptoms associated with benign prostatic hyperplasia in adult males. GNH USA supplies Ofuxal as a licensed, GDP‑compliant international pharmaceutical supplier serving hospitals, pharmacies and clinics worldwide.

GNH USA supplies Ofuxal as a licensed, GDP‑compliant international pharmaceutical supplier serving hospitals, pharmacies and clinics worldwide.

Alfuzosin is used to manage conditions affecting the urinary tract smooth muscle tone, particularly in the context of benign prostatic hyperplasia (BPH).

- Benign prostatic hyperplasia (BPH): Improves urinary flow and reduces symptoms such as urgency, frequency, and nocturia. - Chronic prostatitis: Alleviates discomfort associated with chronic inflammation of the prostate. - Post‑surgical urinary retention: Facilitates the return of normal bladder function after prostate surgery.

Common Side Effects: - Dizziness - Headache - Fatigue - Nasal congestion - Postural hypotension - Nausea

Serious or Rare Side Effects: - Severe hypotension - Syncope - Priapism - Allergic reactions such as rash, itching, or swelling - Angio‑Angl - Angio‑d 

Alfuzosin should be used with caution when patients have: - History ");